Unmet Needs in Complicated Urinary Tract Infections: Challenges, Recommendations, and Emerging Treatment Pathways

Abstract While urinary tract infections (UTIs) are one of the most common types of infections globally, the wide variety of presentations and of severity of disease can make it difficult to manage. The definition for uncomplicated UTIs (uUTIs) is generally regarded as UTIs in healthy, non-pregnant women whereas all other UTIs are considered complicated. There is, however, a lack of consensus definition of complicated UTIs (cUTIs), leading to global differences in management. In addition, the patients who develop complicated UTIs generally have other comorbidities that warrant more urgent intervention. One of the biggest challenges in treating cUTIs is the rise of antimicrobial resistance (AMR). While there have been recent drug approvals for new antibiotic to treat these resistant organisms, a multidisciplinary approach, including regulatory frameworks, provider education and public awareness campaigns, is crucial to limiting unnecessary treatments for asymptomatic bacteriuria (ASB) and uUTIs that can ultimately lead to more severe infections.

[1]  K. Kaye,et al.  Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial. , 2022, JAMA.

[2]  R. Longo,et al.  Intravesical Gentamicin: An Option for Therapy and Prophylaxis against Recurrent UTIs and Resistant Bacteria in Neurogenic Bladder Patients on Intermittent Catheterization , 2022, Antibiotics.

[3]  B. Somani,et al.  Are Intravesical Aminoglycosides the New Gold Standard in the Management of Refractory Urinary Tract Infection: A Systematic Review of Literature , 2022, Journal of clinical medicine.

[4]  P. Eckburg,et al.  Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. , 2022, The New England journal of medicine.

[5]  R. Ohsfeldt,et al.  A Cost-Effectiveness Analysis of Fosfomycin: A Single-Dose Antibiotic Therapy for Treatment of Uncomplicated Urinary Tract Infection , 2022, Health services insights.

[6]  B. Nathanson,et al.  Descriptive Epidemiology and Outcomes of Hospitalizations With Complicated Urinary Tract Infections in the United States, 2018 , 2022, Open forum infectious diseases.

[7]  K. Chien,et al.  Frailty increases the risk for developing urinary tract infection among 79,887 patients with diabetic mellitus and chronic kidney disease , 2021, BMC Geriatrics.

[8]  R. Stafford,et al.  Current Prescribing Practices and Guideline Concordance for the Treatment of Uncomplicated Urinary Tract Infections in Women. , 2021, American journal of obstetrics and gynecology.

[9]  R. Walensky,et al.  Addressing Antibiotic Overuse in the Outpatient Setting: Lessons From Behavioral Economics. , 2021, Mayo Clinic proceedings.

[10]  R. Echols,et al.  Heterogeneity of Recent Phase 3 Complicated Urinary Tract Infection Clinical Trials , 2021, Open forum infectious diseases.

[11]  R. Wunderink,et al.  Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. , 2020, The Lancet. Infectious diseases.

[12]  Z. Tandoğdu,et al.  Epidemiology, definition and treatment of complicated urinary tract infections , 2020, Nature Reviews Urology.

[13]  D. MacFadden,et al.  Improving Decision-making in Empiric Antibiotic Selection (IDEAS) for Gram-negative Bacteremia: A Prospective Clinical Implementation Study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  N. Henderson,et al.  The Natural History and Composition of Urinary Catheter Biofilms: Early Uropathogen Colonization with Intraluminal and Distal Predominance. , 2020, The Journal of urology.

[15]  FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance , 2019, Case Medical Research.

[16]  D. E. Smith,et al.  MULTIPLEX PCR BASED URINARY TRACT INFECTION (UTI) ANALYSIS COMPARED TO TRADITIONAL URINE CULTURE IN IDENTIFYING SIGNIFICANT PATHOGENS IN SYMPTOMATIC PATIENTS. , 2019, Urology.

[17]  T. File,et al.  RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  G. Sakoulas FDA Approves Imipenem-Cilastatin/Relebactam (Recarbrio) for Complicated Intra-Abdominal or Urinary Tract Infections , 2019 .

[19]  Anoop Kumar,et al.  Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. , 2019, Current drug safety.

[20]  A. Flores-Mireles,et al.  Pathophysiology, Treatment, and Prevention of Catheter-Associated Urinary Tract Infection. , 2019, Topics in spinal cord injury rehabilitation.

[21]  J. Horcajada,et al.  Oral and intravenous fosfomycin in complicated urinary tract infections , 2019, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[22]  R. Chou,et al.  Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. , 2019, The Journal of urology.

[23]  L. Rice,et al.  Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  L. Miller,et al.  Once‐Daily Plazomicin for Complicated Urinary Tract Infections , 2019, The New England journal of medicine.

[25]  L. Gesualdo,et al.  Updates on urinary tract infections in kidney transplantation , 2019, Journal of Nephrology.

[26]  M. Harber,et al.  Impact of Urinary Tract Infections in Kidney Transplant Recipients: A 4-Year Single-Center Experience. , 2018, Transplantation proceedings.

[27]  R. Echols,et al.  Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. , 2018, The Lancet. Infectious diseases.

[28]  C. Tebé,et al.  Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections , 2018, Antimicrobial Resistance & Infection Control.

[29]  S. Beatson,et al.  Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial , 2018, JAMA.

[30]  B. Birch,et al.  Use and Effectiveness of Antimicrobial Intravesical Treatment for Prophylaxis and Treatment of Recurrent Urinary Tract Infections (UTIs): a Systematic Review , 2018, Current Urology Reports.

[31]  B. Nathanson,et al.  Development and validation of a bedside instrument to predict carbapenem resistance among gram-negative pathogens in complicated urinary tract infections , 2018, Infection Control & Hospital Epidemiology.

[32]  K. Kaye,et al.  Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial , 2018, JAMA.

[33]  Michael Daniel,et al.  An Implementation Guide to Reducing Overtreatment of Asymptomatic Bacteriuria , 2017, JAMA internal medicine.

[34]  F. Bruyère,et al.  Benefits and Harms of Treatment of Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. , 2017, European urology.

[35]  P. Thokala,et al.  Cost-effectiveness of antibiotic treatment of uncomplicated urinary tract infection in women: a comparison of four antibiotics , 2017, BJGP open.

[36]  A. Cameron,et al.  Gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on intermittent catheterization. , 2017, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[37]  S. Kiertiburanakul,et al.  A randomized controlled trial of sitafloxacin vs. ertapenem as a switch therapy after treatment for acute pyelonephritis caused by extended-spectrum β-lactamase-producing Escherichia coli: A pilot study. , 2017, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[38]  Young Keun Kim,et al.  Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli , 2017, BMC Infectious Diseases.

[39]  A. McDonnell,et al.  Analysis of the potential for point-of-care test to enable individualised treatment of infections caused by antimicrobial-resistant and susceptible strains of Neisseria gonorrhoeae: a modelling study , 2017, BMJ Open.

[40]  Z. Tandoğdu,et al.  An update on classification and management of urosepsis , 2017, Current opinion in urology.

[41]  Linnea A. Polgreen,et al.  The Increase in Hospitalizations for Urinary Tract Infections and the Associated Costs in the United States, 1998–2011 , 2017, Open forum infectious diseases.

[42]  Z. Tandoğdu,et al.  Urinary Tract Infections in Immunocompromised Patients with Diabetes, Chronic Kidney Disease, and Kidney Transplant. , 2016, European urology focus.

[43]  Jason G. Newland,et al.  Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011. , 2016, JAMA.

[44]  Elias Mossialos,et al.  Targeting innovation in antibiotic drug discovery and development: The need for a One Health – One Europe – One World Framework [Internet] , 2016 .

[45]  Z. Tandoğdu,et al.  Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003–2013 , 2015, World Journal of Urology.

[46]  Kayla R. Stover,et al.  A Review of Antibiotic Use in Pregnancy , 2015, Pharmacotherapy.

[47]  D. Paterson,et al.  The emerging threat of multidrug-resistant Gram-negative bacteria in urology , 2015, Nature Reviews Urology.

[48]  S. Hultgren,et al.  Urinary tract infections: epidemiology, mechanisms of infection and treatment options , 2015, Nature Reviews Microbiology.

[49]  A. Salonia,et al.  Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: Results from a multicentre survey. , 2014, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[50]  G. Montini,et al.  Antimicrobial prophylaxis for children with vesicoureteral reflux. , 2014, The New England journal of medicine.

[51]  L. Rice,et al.  MRSA and VRE Colonization in Solid Organ Transplantation: A Meta‐Analysis of Published Studies , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[52]  N. Petersen,et al.  Overtreatment of asymptomatic bacteriuria: identifying provider barriers to evidence-based care. , 2014, American journal of infection control.

[53]  S. Saint,et al.  Strategies to Prevent Catheter-Associated Urinary Tract Infections in Acute Care Hospitals: 2014 Update , 2014, Infection Control & Hospital Epidemiology.

[54]  S. Calderwood,et al.  Catheter-associated urinary tract infection in adults , 2014 .

[55]  B. Zheng,et al.  Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study , 2013, BMJ Open.

[56]  E. Leyten,et al.  Diabetes and the Course of Febrile Urinary Tract Infection , 2013, Diabetes Care.

[57]  Richard Smith,et al.  The true cost of antimicrobial resistance , 2013, BMJ.

[58]  Wendy R. Sanhai,et al.  A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. , 2013, The Lancet. Infectious diseases.

[59]  K. Naber,et al.  Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. , 2011, International journal of antimicrobial agents.

[60]  T. Berney,et al.  Outcome of treated and untreated asymptomatic bacteriuria in renal transplant recipients. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[61]  U. Gafter,et al.  Antibiotic prophylaxis for urinary tract infections in renal transplant recipients: a systematic review and meta‐analysis , 2011, Transplant infectious disease : an official journal of the Transplantation Society.

[62]  Richard Colgan,et al.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  H. Sipahi,et al.  Carbapenem Versus Fosfomycin Tromethanol in the Treatment of Extended-Spectrum Beta-Lactamase-Producing Escherichia Coli-Related Complicated Lower Urinary Tract Infection , 2010, Journal of chemotherapy.

[64]  Sanjay Saint,et al.  Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[65]  Ethan M Balk,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.

[66]  SUPPORTING TABLES,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients. , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[67]  W. Hörl,et al.  Urinary tract infection in renal transplant recipients , 2008, European journal of clinical investigation.

[68]  C. Bonnal,et al.  Bacteriuria in a geriatric hospital: impact of an antibiotic improvement program. , 2008, Journal of the American Medical Directors Association.

[69]  C. Donskey,et al.  Sustained reduction in inappropriate treatment of asymptomatic bacteriuria in a long-term care facility through an educational intervention. , 2008, American journal of infection control.

[70]  S. Vimont,et al.  Acute Pyelonephritis Represents a Risk Factor Impairing Long‐Term Kidney Graft Function , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[71]  M. Haberal,et al.  Urinary tract infections in renal transplant recipients. , 2003, Transplantation proceedings.

[72]  O. Sipahi,et al.  Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. , 2007, International journal of antimicrobial agents.

[73]  E. Hak,et al.  Prediction of complicated urinary tract infections in patients with type 2 diabetes: a questionnaire study in primary care , 2007, European Journal of Epidemiology.

[74]  L. Agodoa,et al.  Late urinary tract infection after renal transplantation in the United States. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[75]  S. Geerlings,et al.  Pathogenesis of bacteriuria in women with diabetes mellitus. , 2002, International journal of antimicrobial agents.

[76]  B. Dobkin,et al.  Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction. , 2002, Archives of physical medicine and rehabilitation.

[77]  M. Loeb,et al.  Development of Minimum Criteria for the Initiation of Antibiotics in Residents of Long-Term–Care Facilities: Results of a Consensus Conference , 2001, Infection Control & Hospital Epidemiology.

[78]  E. Hubbard,et al.  Initiative , 2020, Encyclopedia of Creativity, Invention, Innovation and Entrepreneurship.